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STATE OF MAINE
KENNEBEC, SS

SUPERIOR COURT
CIVIL ACTION
DOCKET NO.

STATE OF MAINE

)
)
Plaintiff
)
)
V.
)
)
THE DANNON COMPANY, INC. )
a Delaware corporation,
)
)
Defendant
)

COMPLAINT FOR PERMANENT
INJUNCTION AND OTHER RELIEF

I. INTRODUCTION
1.

This civil law enforcement proceeding is brought in the name o f the State o f Maine,

in its sovereign capacity, by and through Janet T. Mills, Attorney General (hereinafter “the State,”
“Attorney General,” or “Plaintiff’, pursuant to the Maine Unfair Trade Practices Act, 5 M.R.S.
§205-A, et. seq. (UTPA), and the Attorney General’s common law authority.
2.

The Attorney General has reason to believe that the above-named Defendant has

violated the UTPA by, among other things, failing to substantiate health claims associated with
their yogurt and dairy drink food products and by making claims that its food products can prevent,
treat, cure or mitigate disease.
3.

The Attorney General has reason to believe that this action is in the public interest.

4.

This Complaint is being filed concurrently with an agreed upon final Consent

Judgment.

The Defendant has has agreed to waive the requirement of ten days o f notice of

contemplated legal action as set forth in 5 M.R.S. §209.

II.
5,

JURISDICTION AND VENUE

Jurisdiction and venue are proper in Kennebec County Superior Court pursuant to 5

M.R.S. §209.
III.
6.

PARTIES

Plaintiff, Attorney General Janet T. Mills, is charged with enforcing the UTPA

which prohibits unfair or deceptive acts or practices affecting the conduct of trade or commerce.
Pursuant to 5 M.R.S. §209, the Attorney General may initiate civil enforcement proceedings in the
name of the State to stop violations of the UTPA and to secure such equitable and other relief as
may be appropriate in each case. The Plaintiff brings this action to secure a permanent injunction,
attorneys1 fees, civil penalties, and other equitable relief against the Defendant for engaging in
unfair and deceptive acts or practices in connection with the advertising, marketing, and sale of
their line of food products.
7.

Defendant, the Dannon Company, Inc., is incorporated in Delaware with its

principal place of business in White Plains, New York. The Defendant has manufactured,
marketed, distributed, and sold food products to consumers throughout the United States including
Maine. The Dannon Company, Inc., is a privately-held corporation that is wholly owned by
Groupe Danone, its French parent corporation.
IV.

FACTUAL ALLEGATIONS

Upon information and belief, the State of Maine alleges as follows:
8.

The Defendant has made health-related claims in the marketing, packaging,

advertising, offering, and selling o f their line of Activia yogurt and DanActive food products that

were not substantiated by competent and reliable scientific evidence at the time the claims were
made.
9.

With respect to Activia, the State alleges that the Defendant's health claims, which

asserted a benefit for combating slow intestinal transit time, temporary irregularity, diarrhea,
constipation, bloating, digestive comfort, and other regularity problems, were misleading in that
they were not adequately substantiated at the time the claims were made. Among other things, the
State alleges that fne Defendant did not have adequate substantiation to support claims that Activia
provided select health benefits at one 4 oz. serving per day for two weeks. Further, the State
alleges that the Defendant made direct or implicit claims to mitigate, prevent, or treat certain
diseases relating to digestive health that were unlawful since it is false, misleading, or deceptive to
make such claims for a food, including but not limited to failing to disclose that only drugs
approved by FDA or that comply with an over-the-counter drug monograph can make such claims.
10.

With respect to DanActive, the State alleges that the Defendant’s health claims,

which were positioned to provide “immunity,” a general wellness benefit, and which claimed
antiviral and other “germ fighting” benefits, were misleading in that they were not adequately
substantiated at the time the claims were made. Further, the State alleges that the Defendant made
direct or implicit claims to mitigate, prevent, or treat certain diseases, including the common cold
and the flu, that were unlawful since it is false, misleading, or deceptive to make such claims for a
food, including but not limited to failing to disclose that only drugs approved by FDA or that
comply with an over-the-counter drug monograph can make such claims
11.

Activia is a yogurt product produced and distributed by the Defendant that is sold at

third-party retailers throughout the United States including in Maine at what amounts to a 30% to
50% premium over other yogurt products.

12,

Currently, the Defendant’s Activia product line includes Activia, Activia Fiber,

Activia Light, Activia Drinks, and Activia Dessert, The Defendant’s yogurt products are packaged
in 4 oz, units or 24 oz. tubs in a variety o f flavors including vanilla, strawberry, blueberry, mixed
berry, and prune.
13.

The Defendant began marketing Activia in February 2006 through an extensive

marketing campaign that included television, radio, print, web, and in-store components. From the
initial product launch of Activia, the Defendant positioned Activia as helping to regulate one’s
digestive system.
14.

From the initial product launch, the Defendant emphasized the presence o f

Bifidobacterium animalis D N -173-010, which it marketed under the fanciful, trademarked name
Bifidus Regularis as a distinguishing component ingredient that differentiated Activia from
traditional yogurt products and competitors, At the product launch and thereafter, the Defendant
asserted that “Bifidus Regularis” was a probiotic baceteria strain that helped to contribute to the
purported regularity benefit.
15,

Initially, the Defendant broadly asserted, in advertisements like the one shown

below, that Activia “helps regulate your digestive system . . . naturally” without any disclaimer,
while only holding scientific evidence purportedly showing an effect on consumers with “slow
transit time,” (i.e, the length of time for food to travel from being ingested to eliminated from the
body).

16.

Later the Defendant attempted to qualify the ‘'helps regulate your digestive system”

tagline with an asterisk indicating that its claim referred only to “helping] with slow intestinal
transit time when eaten every day for two weeks as part o f a balanced diet and healthy lifestyle,”
17.

The Defendant claimed that Activia provided a benefit to consumers with normal

transit times when it did not have competent and reliable scientific evidence to substantiate the
claim at the time it was made.
18.

The Defendant implicitly claimed through its broad, unqualified tagline “helps

regulate the digestive system” that Activia provided consumers with bowel movements at fixed,
uniform, or normal intervals when it did not have competent and reliable scientific evidence to
substantiate the claims at the time they were made.
19.

The Defendant also asserted that Activia had an effect on the stomach and the

process of digestion when it did not have competent and reliable scientific evidence to substantiate
the claims at the time they were made. For example, in several nationwide advertisements, the
Defendant used the tagline “two delicious weeks to one happy tummy!”

20.

The Defendant asserted that Activia provided a benefit on bloating, through

advertisements with taglines like “some days does your digestive system feel irregular and
bloated,” when it did not have competent and reliable scientific evidence to substantiate the claim
at the time it was made.
21.

The Defendant implicitly asserted that Activia had antimicrobial benefits, anti-

infectious benefits, and an effect on colon cancer when it could not make these claims without pre
approval as a drug since it is false, misleading, or deceptive to make such claims for a food,
including but not limited to failing to disclose that only drugs approved by FDA or that comply
with an over-the-counter drug monograph can make such claims. For example, the Defendant sent
health professionals Activia-branded informational brochures that prominently highlighted the
Activia brand name and logo, contained the following excerpts:
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22.

DanActive is a dairy drink product produced and distributed by the Defendant that

is sold at third-party retailers throughout the United States including in Maine.
23.

Currently, the Defendant’s DanActive product line includes DanActive and

DanActive Light. DanActive is packaged in 100 mL “daily dose” bottles and comes in a variety of
flavors.
24.

In January 2007, following the release o f Activia, the Defendant launched

DanActive nationally with an extensive nationwide marketing campaign that included television,
radio, print, web, and in-store components. From the initial product launch of DanActive, the
Defendant positioned the product as providing consumers with “immunity” rather than as playing a
modest role in helping support or maintain the immune system. The tagline the Defendant used for
DanActive was “helps strengthen your body’s defenses.”

IMM.y
Helps strengthen your body's defenses.

25.

From the initial product launch, the Defendant emphasized the presence of

Lactobacillus easel strain D N -114 001, which it marketed under the fanciful, trademarked name L.
easel Defensis and later L. easel Immunitas. At the product launch and thereafter, the Defendant
asserted that the strains were probiotics.
26.

The Defendant represented that DanActive would provide health benefits to

consumers with normal functioning immune systems when it did not have competent and reliable
scientific evidence to substantiate the claims at the time that they were made.
27.

The Defendant also represented that DanActive would provide health benefits on

the immune systems of children when it did not have competent and reliable scientific evidence to
substantiate the claims at the time that they were made. Example advertisements are shown below;

28,

In national advertisements, the Defendant directly and implicitly claimed that

DanActive provided germ fighting, antiviral, cold prevention, flu prevention and other disease
prevention benefits that were unlawful since it is false, misleading, or deceptive to make such
claims for a food, including but not limited to failing to disclose that only drugs approved by FDA
or that comply with an over-the-counter drug monograph can make such claims.
29.

In its DanActive advertisements, the Defendant featured situations commonly

associated with cold, flu, or virus transmission including, but not limited to getting sneezed on,
standing in the rain or snow without adequate clothing coverage, digging through a commercial

dumpster, accepting food, money, and other items that have been handled in an unhygienic
manner.
30,

In other national advertisements ran during the peak o f cold and flu season, the

Defendant featured advertisements with depictions of the DanActive bottle with a winter hat and
scarf under the taglines “winter is right around the corner. Are you ready?” and “Bundle Up Your
Body’s Defenses. It’s that time of year.”
BUNDLE u p YOUR
BODY'S DEFENSES

31.

Kroger 10/23 Retail Connection
— Circulation: 2,130,000

In DanActive television advertisements, the Defendant featured an animation

depicting a cellular membrane “fortified with L, casei Immunitas” repelling all or nearly all o f
animated depictions of germs.
32.

In DanActive television advertisements, the Defendant also symbolized a weak

immune system by depicting the actors in grayscale while the rest o f the screenshot remained in
color. In these advertisements, once the actor drank DanActive he or she returned to color and
then conveyed a yellow halo in the same color yellow used on the DanActive bottle and logo. The
use of this animation conveyed that DanActive provides disease protection to consumers.

V.

VIOLATIONS OF LAW

MAINE UNFAIR TRADE PRACTICES ACT
33.

The State incorporates by reference and re-alieges each allegation contained in

paragraphs 1-32.
34.

Defendant’s conduct of advertising, offering for sale, sale and distribution of

commodities as alleged in the Complaint occurred in “trade and commerce” and constitutes the
offering of, or providing of “services” and [commodities] as defined m 5 M.R.S. §206(3).
35.

All of the acts and practices engaged in and employed by the Defendant as alleged

herein, are unfair or deceptive acts or practices affecting the conduct of trade or commerce in
Maine, which are declared unlawful by 5 M.R.S. §207.
36.

Each and every unfair or deceptive act or practice engaged in by the Defendant as

alleged above constitutes a separate violation o f the UTPA as provided by 5 M.R.S, §207.
37.

By making health or other claims without competent and reliable scientific evidence

to substantiate them, the Defendants has violated 5 M.R.S. §207.
38.

By making health claims in their advertisements claiming to prevent, treat, or cure

disease that were unlawful because Defendant failed to obtain advance approval for such claims,
the Defendant has violated 5 M.R.S. §207.
39.

All of the acts and practices engaged in and employed by Defendant as alleged

herein are deceptive or unfair to the consumer or other persons in violation of 5 M.R.S. §207.
VI.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff, State o f Maine, pursuant to the UTPA, the Attorney General’s
general statutory authority, the Attorney General’s common law authority and this Court’s
equitable powers prays:

1.

That this Court adjudge and decree that the Defendant has engaged in the

aforementioned acts or practices which violate the UTPA.
2.

That pursuant to 5 M.R.S. §207, this Court permanently enjoin and restrain the

Defendant from engaging in the aforementioned acts or practices which violate the UTPA and
other laws.
3.

That this Court enter judgment against the Defendant and in favor o f the State for

the reasonable costs and expenses of the investigation and prosecution o f the Defendant’s actions,
including attorneys’ fees and costs, expert and other witness fees, as provided by 5 M.R.S. §203
and §209.
4.

That this Court adjudge and decree that the Defendant pay civil penalties o f not more

than five thousand dollars ($5,000.00) for each and every violation of the UTPA.
5. That all costs in this case be taxed against the Defendant.
6. That no costs be taxed to the State as set forth in 5 M.R.S. §210.
7. That this Court grant the State such other and further relief as this Court deems ju st and
proper.
Dated: December 15, 2010

Respectfully submitted,
JANET T. MILLS
Attorney General

Consumer Division
Maine Bar No,: 6808
Office of the Attorney General
Six State House Station
Augusta, Maine 04333
(207) 626-8897
Attorneys for State of Maine
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STATE OF MAINE

)
)
Pïaintiff
)
)
V.
)
)
THE DANNON COMPANY, INC. )
)
Defendant
)
I.
1.1

CONSENT JUDGMENT

INTRODUCTION

The Plaintiff, the State of Maine, by and through Janet T. Mills, the Attorney

General, and the Defendant, The Dannon Company, Inc., a Delaware corporation, as evidenced
by the signatures of counsel, do consent to the entry of this Judgment and its provisions.
1.2

After engaging in settlement discussions, the Defendant enters into this Judgment

to avoid the time and expense associated with litigation. This is a Judgment for which execution
may issue. This agreement is for settlement purposes only and does not constitute an admission
by Defendant that the law has been violated as alleged in the complaint, or that the facts as
alleged in the complaint, other than the jurisdictional facts, are true.
1.3

The Defendant hereby accepts and expressly waives any defect in connection with

service of process issued to the Defendant by the Plaintiff. The Defendant expressly waives
notice of the State’s intention to file an action.
1.4

This Judgment is entered into by the Defendant as its own free and voluntary act

and with full knowledge and understanding of the nature of the proceedings and the obligations
and duties imposed upon it by this Judgment, and it consents to its entry without further notice,

1

and avers that no offers, agreements or inducements of any nature whatsoever have been made to
it by the Plaintiff or their attorneys or any State employee to procure this Judgment,
1.5

The Defendant has, by signature of counsel hereto, waived any right to add, alter,

amend, appeal, petition for certiorari, or move to reargue or rehear or be heard in connection
with any judicial proceeding upon this Judgment and any and ail challenges in law or equity to
the entry of the Judgment by the courts. If the court elects to hold any hearing on this Judgment,
a representative of the Attorney General’s office will briefly summarize the settlement for the
court. The Defendant agrees to support the Judgment and its terms at any such hearing for
approval.
1.6

In the event the Court shall not approve this Judgment, this Judgment shall be of

no force and effect against either party.
II.
2.1

DEFINITIONS

As used in this Judgment, the following words or terms shall have the following

meanings:
A.

“Adequate and Well-Controlled Human Clinical Study” means a
human clinical study conducted by persons qualified by training and
experience to conduct such study. Such study shall be randomized, and
unless it can be demonstrated that blinding or placebo control cannot be
effectively or ethically implemented given the nature of the intervention,
shall be double-blind and placebo-controlled.

B.

“Advertise,” “Advertisement,” or “Advertising,” means any written,
oral, graphic, or electronic statement, illustration, or depiction, including
Labels or Labeling, that is designed to create interest in the purchasing of,

2

impart information about the attributes of, publicize the availability of, or
affect the sale or use of, the Defendant’s goods or services, whether the
statement appears in Labels or Labeling, in a brochure, newspaper,
magazine, free standing insert, marketing kit, leaflet, mailer, book insert,
letter, catalogue, poster, chart, billboard, electronic mail, website or other
digital format, slide, radio, broadcast television, cable television, or
commercial or infomercial whether live or recorded.
C.

“And” and “Or” shall be construed conjunctively or disjunctively as
necessary, and to make the applicable phrase or sentence inclusive rather
than exclusive.

D.

“Attorney General” means Office of the Maine Attorney General,

E.

“Covered Conduct” shall mean the Defendant’s Advertising, Marketing
and Labeling practices regarding the Covered Products through the
Effective Date of this Judgment.

F.

“Covered Product” or “Covered Products” shall mean (i) any yogurt,
including but not limited to Activia yogurt; (Si) any dairy drink; and (iii)
any food or drink not covered by the foregoing that contains a Probiotic,
including, but not limited to, DanActive.

G.

“Defendant” or “Dannon” shall refer to The Dannon Company, Inc., a
Delaware corporation with its principal place of business in White Plains,
NY. For purposes of this Consent Judgment only, the term includes its

3

successors and assigns and their officers, and each of the above’s agents,
representatives, and employees.
H.

“Disease” shall refer to damage to an organ, part, structure, or system of
the body such that it does not function properly (e.g., cardiovascular
disease), or a state of health leading to such dysfunctioning (e.g.
hypertension); except that diseases resulting from essential nutrient
deficiencies (e.g., scurvy, pellagra) are not included in this definition.

I.

“Effective Date” shall refer to the date that this Judgment is signed and
fully executed by the parties and approved by the Court. However, the
Effective Date as it affects existing Labeling shall be one hundred twenty
(120) days after this Judgment is signed and fully executed by the parties
and approved by the Court. AH Covered Product manufactured after the
one hundred twenty (120) days shall have the revised Labeling. However,
the Effective Date for existing print Advertisements and broadcast
Advertisements shall be 90 days after this Judgment is signed and fully
executed by the parties and approved by the Court.

J.

“Essentially Equivalent Product” means a product that contains the
identical ingredients, except for inactive ingredients (e.g., inactive binders,
flavors, preservatives, colors, fillers, excipients), in the same form and
dosage, and with the same route of administration (e.g., orally,
sublingually), as the Covered Product; provided that the Covered Product
may contain additional ingredients or other differences in formulation to
affect taste, texture, or nutritional value (so long as the other differences

4

do not change the form of the Product or involve the ingredients from
which the functional benefit is derived), if reliable scientific evidence
generally accepted by experts in the field demonstrates that the amount of
additional ingredients, combination of additional ingredients, and any
other differences in formulation are unlikely to impede or inhibit the
effectiveness of the ingredients in the Essentially Equivalent Product.
K.

“Including” shall mean including, without limitation.

L.

“Label” shall mean a display of written, printed or graphic matter upon
the immediate container of any article, or on the outside container or
wrapper, if any, of the retail package of such article.

M.

“Labeling” shall mean all Labels and other written, printed, or graphic
matter upon any article or any of its containers or wrappers, or
accompanying such article.

N.

“Marketing” shall mean any act or process or technique of promoting,
offering, selling or distributing a product or service.

O.

“Probiotics” shall mean live microorganisms, which when administered
in adequate amounts, confer a health benefit on the host, excluding the
cultures Streptococcus thermophilus and Lactobacillus bulgaricus,

P.

“Settling States” shall mean and include; Alaska, Arizona, Arkansas,
Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois,
Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts,
Michigan, Missouri, Montana, Nebraska, Nevada, New Hampshire, New
Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Oregon,

5

Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee,
Texas, Vermont, Washington, West Virginia and Wisconsin.
Q.

“State,” “State of Maine,” or “Attorney General” refers to the Plaintiff
and shall mean the Office of the Maine Attorney General.

III.
3.1.

JURISDICTION

Jurisdiction of this Court over the subject matter and over the Defendant for the

purpose of entering into and enforcing this Judgment is admitted. Jurisdiction is retained by this
Court for the purpose of enabling the State to apply to this Court for such further Judgments and
directions as may be necessary or appropriate for the construction, modification or execution of
this Judgment, including the enforcement of compliance therewith and remedies, penalties and
sanctions for violation thereof The Defendant agrees to pay all court costs and attorneys’ fees
associated with any successful petition to enforce any provision of this Judgment against the
Defendant.
IV.
4.1

VENUE

Pursuant to 5 M.R.S. §209, venue as to all matters between the parties relating

hereto or arising out of this Judgment shall be in Kennebec County, Maine.
V.
5 .1
5.2

DEFENDANT

The Defendant warrants and represents that it is the proper party to this Judgment.
The Defendant represents and warrants that the execution and delivery of this

Judgment is its free and voluntary act, and that this Judgment is the result of good faith
negotiations.
5.3

The Defendant represents and warrants that signatories to this Judgment have
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authority to act for and bind the Defendant.
5.4

The Defendant acknowledges that it understands that the State and this Court

expressly rely upon all representations and warranties in this Judgment. The Defendant further
acknowledges and understands that if any Defendant makes any false or deceptive representation
or warranty, the State has the right to vacate or set aside this Judgment, inter alia, in whole or in
part, and to move that the Defendant making such false, or deceptive representation(s) or
warranty(ies) be held in contempt and to seek sanctions and remedies under any other law,
regulation or rule, together with any and all such other sanctions, remedies or relief as may be
available to the State in law or equity, if the State so elects.
VI.
6.1

APPLICATION OF JUDGMENT

The Defendant agrees that the duties, responsibilities, burdens and obligations

undertaken in connection with this Judgment shall apply to The Dannon Company, inc., its
successors and assigns, and their officers, and each of the above’s agents, representatives, and
employees.
VII.
7.1

PERMANENT INJUNCTION

All of the requirements of this section, Part Vii, are cumulative and any

representation that Defendant makes shall comply with each and every provision in this Part VÌI.
Except as provided in paragraph 7.2, upon entry of this Judgment, the Defendant, directly or
through any corporation, partnership, subsidiary, division, trade name, or other device, is hereby
permanently enjoined and restrained pursuant to 5 M.R.S. §209 from:
A.

Making any express or implied representation in connection with the
Advertising, Marketing, or Labeling of a Covered Product, including
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through the use of a product name, endorsement, depiction, or illustration,
which in the context of the Labeling, Advertisement, or Marketing
material, directly states or implies that such Product may be used in the
diagnosis, cure, mitigation, treatment, or prevention of a Disease,
including but not limited to:
1.

Using:
a.

the term L. casei Defensis;

b.

the phrase, “strengthens your body’s defenses;” or

c.

any depictions, characters or vignettes that imply active
germ fighting;

2.

Representing that any Covered Product can be used to treat,
mitigate, cure or prevent diarrhea; provided, however, a
structure/function claim that the Covered Product supports or
promotes relief from temporary or occasional diarrhea is not
prohibited, if the Defendant possesses and relies upon competent
and reliable scientific evidence that is sufficient in quality and
quantity based on standards generally accepted in the relevant
scientific fields when considered in light of the entire body of
relevant and reliable scientific evidence that substantiates that the
representation is true. For purposes of this Paragraph, competent
and reliable scientific evidence means tests, analyses, research, or
studies that have been conducted and evaluated in an objective
manner by qualified persons and are generally accepted in the
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profession to yield accurate and reliable results.
3.

Representing that any Covered Product can be used to treat,
mitigate, cure, or prevent constipation, including through the use of
depictions to symbolize relief from constipation; provided,
however a structure/function claim that the Covered Product
supports or promotes relief from temporary and occasional
constipation is not prohibited, if the Defendant possesses and relies
upon competent and reliable scientific evidence that is sufficient in
quality and quantity based on standards generally accepted in the
relevant scientific fields when considered in light of the entire
body of relevant and reliable scientific evidence that substantiates
that the representation is true. For purposes of this Paragraph,
competent and reliable scientific evidence means tests, analyses,
research, or studies that have been conducted and evaluated in an
objective manner by qualified persons and are generally accepted
in the profession to yield accurate and reliable results.

4.

Using the word “immunity,” or the phrase, “L. casei immunitas”,
provided however, that a structure/function claim can be made for
the word “immunity,” or the phrase

casei immunitas” in which

(a) the Defendant clearly and conspicuously modifies the word
“immunity,” or the phrase, “L. casei Immunitas” with a statement
that the Covered Product merely helps to promote, support or
maintain the immune system of persons who consume a Covered

9

Product and (b) the Defendant possesses and relies upon competent
and reliable scientific evidence that is sufficient in quality and
quantity based on standards generally accepted in the relevant
scientific fields, when considered in light of the entire body of
relevant and reliable scientific evidence, to substantiate that the
representation is true. For purposes of this paragraph, competent
and reliable scientific evidence means tests, analyses, research, or
studies that have been conducted and evaluated in an objective
manner by qualified persons and are generally accepted in the
profession to yield accurate and reliable results.
5.

Citing, summarizing, or linking to clinical studies or research in
the Labeling of a Covered Product if the citation, summary, or link
to the clinical studies or research, in the context of the Labeling as
a whole, implies that a Covered Product or an ingredient in a
Covered Product treats, mitigates, cures, or prevents a Disease,
e.g., placement on the immediate product labeling or packaging,
inappropriate prominence, or lack of relationship to the Covered
Producf s express claims.

6.

Depicting a cellular wall fortified with a Covered Product that
repels all, or nearly all, of the depictions of germs.

B.

Making any express or implied representation in connection with the
Advertising, Marketing, or Labeling of a Covered Product, including
through the use of a product name, endorsement, depiction, or illustration,
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that such Product reduces the likelihood of getting a cold or the flu, which
in the context of the Labeling, Advertisement, or Marketing material,
directly states or implies that any Covered Product can be used to treat,
mitigate, or prevent a cold or the flu.
C.

Making any express or implied representation in connection with the
Advertising, Marketing or Labeling of Activia yogurt, including through
the use of a product name, endorsement, depiction, or illustration, that
Activia yogurt relieves temporary irregularity or helps with slow intestinal
transit time, unless the representation is non-misleading, conveys that
eating three servings a day is required to obtain the benefit and, at the time
the claim is made, the Defendant possesses and relies upon competent and
reliable scientific evidence that substantiates that the representation is true.
Provided, however, that nothing in this Paragraph shall prohibit Defendant
from representing that such benefit can be achieved from eating less than
three servings a day if such claim is non-misleading and Defendant
possesses and relies upon competent and reliable scientific evidence that
substantiates that the representation is true.
For purposes of paragraph 7.1(C), competent and reliable scientific
evidence shall consist of at least two Adequate and Well-Controlled
Human Clinical Studies of Activia yogurt, or of an Essentially Equivalent
Product, conducted by different researchers, independently of each other,
that conform to acceptable designs and protocols and whose results, when
considered in light of the entire body of relevant and reliable scientific
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evidence, are sufficient to substantiate that the representation is true.
Defendant shall have the burden of proving that a product satisfies the
definition of Essentially Equivalent Product.
D.

Making any express or implied representation in connection with the
Advertising, Marketing or Labeling of any Covered Product other than
Activia yogurt, including through the use of a product name, endorsement,
depiction, or illustration, that such Product relieves temporary irregularity
or helps with slow intestinal transit time, unless the representation is non
misleading and, at the time the claim is made, the Defendant possesses and
relies upon competent and reliable scientific evidence that substantiates
that the representation is true. For purposes of paragraph 7.1 (D),
competent and reliable scientific evidence shall consist of at least two
Adequate and Well-Controlled Human Clinical Studies of the Covered
Product, or of an Essentially Equivalent Product, conducted by different
researchers, independently of each other, that conform to acceptable
designs and protocols and whose results, when considered in light of the
entire body of relevant and reliable scientific evidence, are sufficient to
substantiate that the representation is true. Defendant shall have the
burden of proving that a product satisfies the definition of Essentially
Equivalent Product.

E.

Making any express or implied representation in connection with the
Advertising, Marketing or Labeling o f a Covered Product, including
through the use of a product name, endorsement, depiction or illustration,
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about the health benefits, performance, efficacy or safety of a Covered
Product, unless the representation is non-misleading, and, at the time the
claim is made, the Defendant possesses and relies upon competent and
reliable scientific evidence that is sufficient in quality and quantity based
on standards generally accepted in the relevant scientific fields when
considered in light of the entire body of relevant and reliable scientific
evidence to substantiate that the representation is true.
For the purposes of paragraph 7.1(E), competent and reliable scientific
evidence means tests, analyses, research, or studies that have been
conducted and evaluated in an objective manner by qualified persons and
are generally accepted in the profession to yield accurate and reliable
results.
F.

Making, in connection with the Advertising, Marketing, or Labeling of a
Covered Product, any express or implied representation about the
existence, contents, methodology, statistical analyses, study scope,
validity, results, conclusions, or interpretations of any test, study, or
research that is false, misleading or deceptive, or that is misleading or
deceptive when considered together with other representations or
depictions.

G.

Using, in connection with the Labeling of a Covered Product, the term
Bifidus Regularis™, or any other fanciful term that expressly or impliedly
represents that a Covered Product helps regulate the digestive system
unless the Defendant clearly and conspicuously identifies the true
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scientific name of the bacteria, including its genus, species and strain.
H.

Using, in connection with the Labeling of a Covered Product, the term L.
casei Immunitas™, or any other fanciful term that expressly or impliedly
represents that a Covered Product supports, promotes, or maintains the
functioning of the immune system unless the Defendant clearly and
conspicuously identifies the true scientific name of the bacteria, including
its genus, species and strain.,

7.2

Additional Terms Governing Injunctive Relief
A.

Notwithstanding any of the foregoing provisions, Defendant, directly or
through any corporation, partnership, subsidiary, division, trade name, or
other device, is hereby permanently enjoined and restrained from making
any express or implied statement(s) in connection with the Advertising,
Marketing or Labeling of any Covered Product that is false, misleading, or
deceptive, or that is misleading or deceptive when considered together
with other representations or depictions; and from omitting any material
information such that an express or implied statement made by the
Defendant, directly or through any corporation, partnership, subsidiary,
division, trade name, or other device, is misleading or deceptive.

B.

Nothing in this Judgment shall prohibit Defendant, directly or through any
corporation, partnership, subsidiary, division, trade name, or other device,
from making any lawful, non-misleading, and non-deceptive
representation for any Covered Product that is: (i) specifically permitted in
Labeling for such Product by regulations promulgated by the Food and
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Drug Administration pursuant to the Nutrition Labeling and Education Act
of 1990; (ii) lawful for the Covered Product under the Federal Food Drug
and Cosmetic Act; (in) lawful for the Covered Product under any final
regulation promulgated by the Food and Drug Administration; (iv) lawful
for the Covered Product under any new drug application applicable to
such Product approved by the Food and Drug Administration; (v) part of
the lawful marketing for the Covered Product of a homeopathic drug; (vi)
part of the lawful marketing for the Covered Product of a Medical Food
under the Orphan Drug Amendments of 1998; or (vii) lawful for the
Covered Product under a FDA monograph of an over-the-counter drug.
The failure of the FDA, FTC, or other law enforcement agency to take an
enforcement action, or the mere presence of a representation, statement, or
claim in the marketplace does not mean a representation, statement, or
claim is lawful.

VIII. COMPLIANCE
8.1

Pursuant to 5 M.R.S, §209, the Defendant shall, in connection with the

Advertising, promotion, offering for sale, or distribution in or from Maine of any Covered
Product:
A.

Take reasonable steps sufficient to monitor and ensure that the Defendant
complies with this Judgment. In conducting periodic monitoring of
compliance, the Defendant shall document and retain sufficient evidence
to detail and substantiate its monitoring efforts and produce such
documentation as may be requested by the State within thirty (30) days of
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such a request.
B.

Conduct periodic reasonable monitoring of representations made by the
Defendant concerning any Covered Product when the relevant actors are
engaged in sales or other customer service functions, including
representations made orally or through electronic communications. For a
period of five (5) years from the date of entry o f this Judgment, in
conducting periodic monitoring of the representations made by the
Defendant concerning any Covered Product, the Defendant shall
document and retain sufficient evidence to detail and substantiate its
monitoring efforts and produce such documentation to the State within
thirty (30) days of such a request.

C.

Conduct periodic reasonable monitoring of representations made about
any Covered Product on all internet websites operated or maintained by
the Defendant or anyone doing so on their behalf. For a period of five (5)
years from the date of entry o f this Judgment, in conducting periodic
monitoring of representations made about any Covered Product on
Internet websites operated or maintained by the Defendant or anyone
doing so on its behalf, the Defendant shall document and retain sufficient
evidence to detail and substantiate their monitoring efforts and produce
such documentation and records as may be requested by the State within
thirty (30) days of such a request.

D.

Take appropriate disciplinary action against any employee or agent who
knew or should have known that he or she had engaged in any conduct
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prohibited by this Judgment, up to and including termination of any such
employment or agency relationship, within a reasonable period of time not
to exceed thirty (30) days after the Defendant knows or should have
known that such person is, or has been, engaging in such conduct.
E.

Within sixty (60) days after entry of this Judgment, send an exact copy of
this Judgment to each of the Defendant’s directors, officers, and any
employee, agent, or third party who creates, reviews, or edits the
Defendant’s Advertising, Marketing or Labeling of Covered Products. The
Defendant shall document and retain sufficient evidence to confirm
distribution as required by this paragraph and shall produce such
documentation to the State within thirty (30) days of such a request.

F.

Within 60 days of entry of this Judgment, institute a reasonable program
of surveillance that is adequate to reveal whether the Defendant is
disseminating in or from Maine any Advertising, Marketing or Labeling
material that contains any representation that violates the provisions of this
Judgment. For a period of five (5) years from the date of entry of this
Judgment, the Defendant shall document and retain sufficient evidence to
detail and substantiate its program of surveillance and shall produce such
documentation to the State within thirty (30) days of such a request.

G.

Promptly, and in a reasonable manner, investigate any information the
Defendant receives that any retailer or other third party in Maine is using
or disseminating any Advertisements or Marketing material, or making
any oral statements, that violate the provisions of this Judgment, and send
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Exhibit A to any retailer or other third party whose Advertisements or
Marketing materials of a Covered Product may violate the terms of this
Judgment if made by the Defendant. For a period o f five (5) years from
the date o f entry o f this Judgment, the Defendant shall document and
retain sufficient evidence to detail and substantiate their investigation
efforts and shall produce such documentation to the State within thirty
(30) days of such a request.

IX.
9.1

PAYMENT TO THE STATES

No later than thirty (30) days after the Effective Date o f this Judgment, Dannon

shall pay a total amount of $21 million to the Office of the Attorney General o f Tennessee
through electronic funds transfer. The Tennessee Attorney General shall divide and distribute
these funds to each Signatory Attorney General o f the Multistate Working Group1 in an amount
to be designated by, and in the sole discretion of, the Multistate Executive Committee.

Said

payment shall be used by the States as and for attorneys’ fees and other costs o f investigation and
litigation, or to be placed in, or applied to, the consumer protection enforcement fund, including
future consumer protection enforcement, consumer education, litigation or local consumer aid
fund or revolving fund, used to defray the costs of the inquiry leading hereto, or for other uses
permitted by state law including contributions to nutrition and nutrition education programs, at
the sole discretion of each Signatory Attorney General.*2

! The Working Group consists of Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida,
Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan,
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio,
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Tennessee, Vermont,
Washington, West Virginia and Wisconsin.
2 The Executive Committee consists of Arizona, Florida, Kentucky, North Carolina, Ohio, Oregon, Texas,
Tennessee, and Wisconsin.
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X.
10.1

GENERAL PROVISIONS

The acceptance of this Judgment by the State shall not be deemed approval by the

State of any of the Defendant's advertising or business practices. Further, neither the Defendant
nor anyone acting on its behalf shall state or imply, or cause to be stated or implied, that the State
or any other governmental unit of the State has approved, sanctioned or authorized any practice,
act, advertisement or conduct of the Defendant.
10.2

This Judgment may only be enforced by the State, the Defendant, and this Court.

10.3

The titles and headers to each section of this Judgment are for convenience

purposes only and are not intended by the parties to lend meaning to the actual provisions of the
Judgment.
10.4

Nothing in this Judgment shall limit the State’s right to obtain information,

documents or testimony from the Defendant pursuant to any state or federal law, regulation or
rule.
10.5

Nothing in this Judgment shall be construed to limit the authority of the Attorney

General to protect the interests of the State or consumers. Except as provided in Section XR of
this Judgment, this Judgment shall not bar the State, or any other governmental entity from
enforcing laws, regulations or rules against the Defendant.
10.6

it is the intent of the Parties that this Judgment not be admissible in other actions

or binding on the Defendant in any respect other than in connection with the enforcement of this
Judgment.
10.7

No waiver, modification, or amendment of the terms of this Judgment shall be

valid or binding unless made in writing, signed by the party to be charged, approved by this
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Court and then only to the extent specifically set forth in such written waiver, modification or
amendment.
10.8

Any failure by any party to this Judgment to insist upon the strict performance by

any other party of any of the provisions of this Judgment shall not be deemed a waiver of any of
the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance of any and all of the provisions of this
Judgment and the imposition of any applicable penalties, including but not limited to contempt,
civil penalties as set forth in 5 M.R.S. §209 and/or the payment of attorneys fees to the State and
other applicable state law.
10.9

If any clause, provision or section of this Judgment shall, for any reason, be held

illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall not affect
any other clause, provision or section of this Judgment and this Judgment shall be construed and
enforced as if such illegal, invalid or unenforceable clause, section or other provision had not
been contained herein.
10.10 Time shall be of the essence with respect to each provision of this Judgment that
requires action to be taken by the Defendant within a stated time period or upon a specified date.
10.11 Nothing in this Judgment shall be construed to waive any claims of Sovereign
immunity the State may have in any action or proceeding,
10.12 This Judgment sets forth the entire agreement between the parties, and there are
no representations, agreements, arrangements, or understanding, oral or written, between the
parties relating to the subject matter of this Judgment which are not fully expressed hereto or
attached hereto.
10.13 The Defendant will not participate, directly or indirectly, in any activity or form a
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separate entity or corporation for the purpose of engaging in acts or practices in whole or in part
in the State which are prohibited in this Judgment or for any other purpose which would
otherwise circumvent any part of this Judgment or the spirit or purposes of this Judgment.
10.14 The Defendant has provided the State with certain documents, advertisements,
and contracts. The Defendant acknowledges and agrees that providing these documents to the
Slate(s) in no way constitutes the State’s pre-approval, review for compliance with state or
federal law, or with this Judgment, or a release of any issues relating to such documents.
10.15 The Defendant further agrees to execute and deliver all authorizations, documents
and instruments which are necessary to carry out the terms and conditions of this Judgment.
10.16 This document may be executed in any number of counterparts and by different
signatories on separate counterparts, each of which shall constitute an original counterpart hereof
and all of which together shall constitute one and the same document. One or more counterparts
of this Judgment may be delivered by facsimile or electronic transmission with the intent that it
or they shall constitute an original counterpart thereof.
XI.
11.1

COMPLIANCE WITH ALL LAWS

Nothing in this Judgment shall be construed as relieving the Defendant of the

obligation to comply with all state and federal laws, regulations or rules, nor shall any of the
provisions uf this Judgment be deemed to be permission to engage in any acts or practices
prohibited by such law, regulation, or rule.
11.2

Nothing in this Judgment shall require the Defendant to: (A) take an action that is

otherwise prohibited by the Constitution, laws or rules or regulations made there under, of the
United States or Maine; or (B) fail to take an action which is so required.
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XII.

12.1

RELEASE

Nothing in this Judgment shall impair or limit the private right of action that any

consumer, person, or entity may have against the Defendant,
12.2

By execution of this Judgment and following a full and complete payment to the

States, the State of Maine releases and forever discharges to the fullest extent of the law, the
Defendant, as defined above, from the following: all civil claims, causes of action, damages,
restitution, fines, costs, and penalties that the Maine Attorney General could have asserted
against the Defendant under the Maine Unfair Trade Practices Act, 5 M.R.S. §207 et.seq.
resulting from the Covered Conduct up to and including the Effective Date that is the subject of
this Judgment.
12.3

Notwithstanding any term of this Judgment, any and all of the following forms of

liability are specifically reserved and excluded from the Release in Section 12,2 as to any entity
or person, including the Defendant:
A.

Any criminal liability that any person or entity, including the Defendant,
has or may have to the State of Maine.

B.

Any civil or administrative liability that any person or entity, including the
Defendant, has or may have to the State of Maine under any statute,
regulation or rule not expressly covered by the release in Section 12.2
above, including but not limited to, any and all of the following claims:

C.

(i)

State or federal antitrust violations; or

(ii)

State or federal tax claims.

Any liability under the State of Maine’s above-cited consumer protection
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laws that any person and/or entity, including the Defendant has or may
have to individual consumers, persons, or entities.
XIII, DISPUTES REGARDING COMPLIANCE
13.1

For the purposes of resolving disputes with respect to compliance with this

Judgment, should the Attorney General have a reasonable basis to believe that the Defendant has
engaged in a practice that violates a provision of this Judgment subsequent to the Effective Date
of this Judgment, then the Attorney General shall notify the Defendant in writing of the specific
objection, identify with particularity the provisions of this Judgment that the practice appears to
violate, and give the Defendant thirty (30) calendar days to respond to the notification; provided,
however, that the Attorney General may take any action where the Attorney General concludes
that, because of the specific practice, a threat to the health or safety of the public requires
immediate action.
13.2

Upon receipt of written notice and within the thirty (30) calendar-day period, the

Defendant shall provide a good faith written response to the Attorney General's objection. The
response shall include an affidavit containing either:
A.

A statement explaining why the Defendant believes it is in compliance
with the Judgment; or

B.

A detailed explanation of how the alleged violation(s) occurred; and
i.

A statement that the alleged violation has been remedied and how
it has been remedied; or

ii.

A statement that the alleged violation cannot be reasonably
remedied within thirty (30) calendar days from receipt of the
notice, but (1) the Defendant has begun to take corrective action to
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remedy the violation; (2) the Defendant is pursuing such corrective
action with reasonable and due diligence; and (3) the Defendant
has provided the Attorney General with a detailed and reasonable
time table for remedying the alleged violation.
13.3

Nothing herein shall prevent the Attorney General from agreeing in writing to

provide the Defendant with additional time beyond the thirty (30) calendar-day period to respond
to the notice.
13.4

Nothing herein shall be construed to exonerate any failure to comply with any

provision of this Judgment after the date of entry or to compromise the authority of the Attorney
General to initiate a proceeding for failure to comply. Further, nothing in this section shall be
construed to limit the authority of the Attorney General to protect the interests of the State.
13.5

The Attorney General represents that he or she will seek enforcement of the

provisions of this Judgment with due regard for fairness and, in so doing, shall take into account
efforts that the Defendant has taken to remedy any claimed violation of this Judgment.
13.6

Upon giving the Defendant thirty (30) calendar days to respond to the notification

described in Paragraph 13.1 above, the Attorney General shall be permitted to request and the
Defendant shall produce relevant, non-privileged, non-work-product records and documents in
the possession, custody or control of the Defendant that relate to its compliance with each
provision of this Judgment as to which legally sufficient cause has been shown.
XIV. NOTIFICATION TO STATE
14,1

For five (5) years following execution of this Judgment, the Defendant shall

notify the State, in writing at least thirty (30) calendar days prior to the effective date of any
proposed changes in its corporate structure, such as dissolution, assignment, or sale resulting in
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the emergence of a successor corporation or firm, the creation or dissolution of subsidiaries, or
any other changes in the Defendant’s status that may impact in any way compliance with
obligations arising out of this Judgment.
14.2

Any notices required to be sent to the State or the Defendant by this Judgment

shall be sent by United States mail, certified mail return receipt requested or other nationally
recognized courier service that provides for tracking services and identification of the person
signing for the document. The documents shall be sent to the following addresses:

For the State Attorney General:
Consumer Division
Office of the Attorney General
#6 State House Station
Augusta, ME 04333-0006
For the Defendant:
Sarah Reznek
Bingham McCutchen LLP
202OK Street, NW
Washington, DC 20006-1806

XV.
15.1

PAYMENT OF COURT COSTS

All court costs associated with this action and any other incidental costs or

expenses incurred in this action thereby shall be borne by the Defendant. No costs shall be taxed
to the State. Further, no discretionary costs shall be taxed to the State.
XVI. PENALTY FOR FAILURE TO COMPLY
16.1

Any failure by the Defendant to comply with or any violation by the Defendant of

the terms of this Consent Judgment shall be punishable in accordance with 5 M.R.S. §209 and
the State of Maine shall be free to pursue any and all remedies contained within 5 M.R.S. §209.
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IT IS SO O R D E R E D , A DJUDG ED, AN D D E C R E E D .
c:

ICE, SUPER

R COURT

JOINTLY APPROVED AND
SUBMITTED FOR ENTRY:

Respectfully submitted,
JANET T. MILLS
Attorney General

Civil Rights Education and Enforcement
Maine Bar No.: 6808

Office of the Attorney General
Six State House Station
Augusta, Maine 04333
(207) 626-8897
Attorneys for State of Maine
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FOR THE DANNON COMPANY, INC.

Bingham McCutchen LLP
2020 IC Street, N.W.
Washington, D.C. 20006
Tel: (202) 373-6218
Fax: (202)373-6491
Email: nicholas.gess@bingham.com
ME Bar No. 002504
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TH E HANNON COMPANY, IN C
100 Hillside Avenue
White Plains, NY 10603
Phone: 914-872-8400
Fax: 914-872“1554

By:
Kenneth Stride
Title: Vice President and Secretary
Date: December 9, 2010

Bingham McCutchen LLP
National Counsel for T H E BANNON COM PANY, INC.

Washington, DC 20006-1806
Phone: 202-373-6171
Fax: 202-373-6001
Date:

A/73586972.1
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GOVERNMENT-ORDERED DISCLOSURE
[on Dannon Company, Inc,, letterhead]
[Insert Date]
[Addressee]
Dear Dannon Company, Inc., Distributor, Reseller, or Retailer:
The Dannon Company, Inc., (Dannon) recently reached a settlement with the
Attorneys General of thirty-eight states and the State of Hawaii, Office of Consumer Protection
(State AGs) resolving an investigation into what the State AGs believed to be unsubstantiated
and/or deceptive and unlawful claims concerning Dannon’s Activia and DanActive products,
Although we dispute the views of the State AGs and deny any wrongdoing, we have agreed to
resolve the State AGs’ investigation.
Dannon will work with you to ensure the advertisements that you distribute are in
compliance with the Settlement Agreement. To comply with the Settlement Agreement reached
with the State AGs, Dannon offers its assistance in ensuring that the advertising or promotional
materials that you disseminate regarding Activia and DanActive products will be in compliance
with the terms of the Settlement Agreement, including claims identified in the Consent
Judgment. Such claims about Activia and DanActive products may only be made if they are
true, adequately substantiated and otherwise permitted by law as stated in the Settlement
Agreement.
A copy of the settlement with the State AGs is attached. If you have any
questions, please call [insert name and telephone numbers of the responsible Dannon Company,
Inc. Attorney or Officer],
Sincerely,
The Dannon Company, Inc.
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STATE OF MAINE
KENNEBEC, SS

SUPERIOR COURT
CIVIL ACTION
DOCKET NO.

STATE OF MAINE

)
)
Plaintiff
)
)
V.
)
)
THE DANNON COMPANY, INC. )
)
Defendant
)
I.
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The Plaintiff, the State of Maine, by and through Janet T. Mills, the Attorney

by the signatures of counsel, do consent to the entry of this Judgment and its provisions.
After engaging in settlement discussions, the Defendant enters into this Judgment

to avoid the time and expense associated with litigation. This is a Judgment for which execution
may issue. This agreement is for settlement purposes only and does not constitute an admission
by Defendant that the law has been violated as alleged in the complaint, or that the facts as
alleged in the complaint, other than the jurisdictional facts, are true.
1.3

The Defendant hereby accepts and expressly waives any defect in connection with

service of process issued to the Defendant by the Plaintiff. The Defendant expressly waives
notice of the State's intention to file an action.
1.4
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General, and the Defendant, The Dannon Company, Inc., a Delaware corporation, as evidenced

1.2

m

This Judgment is entered into by the Defendant as its own free and voluntary act

and with full knowledge and understanding of the nature of the proceedings and the obligations
and duties imposed upon it by this Judgment, and it consents to its entry without further notice,
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and avers that no offers, agreements or inducements of any nature whatsoever have been made to
it by the Plaintiff or their attorneys or any State employee to procure this Judgment.
1.5

The Defendant has, by signature of counsel hereto, waived any right to add, alter,

amend, appeal, petition for certiorari, or move to reargue or rehear or be heard in connection
with any judicial proceeding upon this Judgment and any and all challenges in law or equity to
the entry of the Judgment by the courts. If the court elects to hold any hearing on this Judgment,
a representative of the Attorney General’s office will briefly summarize the settlement for the
court. The Defendant agrees to support the Judgment and its terms at any such hearing for
approval.
1.6

In the event the Court shall not approve this Judgment, this Judgment shall be of

no force and effect against either party.
II.
2,1

DEFINITIONS

As used in this Judgment, the following words or terms shall have'the following

meanings:
A.

“Adequate and Well-Controlled Human Clinical Study” means a
human clinical study conducted by persons qualified by training and
experience to conduct such study. Such study shall be randomized, and
unless it can be demonstrated that blinding or placebo control cannot be
effectively or ethically implemented given the nature of the intervention,
shall be double-blind and pi ace bo-control led.

B.

“Advertise,” “Advertisement,” or “Advertising,” means any written,
oral, graphic, or electronic statement, illustration, or depiction, including
Labels or Labeling, that is designed to create interest in the purchasing of,
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impart information about the attributes of, publicize the availability of, or
affect the sale or use of, the Defendant’s goods or services, whether the
statement appears in Labels or Labeling, in a brochure, newspaper,
magazine, free standing insert, marketing kit, leaflet, mailer, book insert,
letter, catalogue, poster, chart, billboard, electronic mail, website or other
digital format, slide, radio, broadcast television, cable television, or
commercial or infomercial whether live or recorded.
C.

“And” and “Or” shall be construed conjunctively or disjunctively as
necessary, and to make the applicable phrase or sentence inclusive rather
than exclusive.

D.

“Attorney General” means Office of the Maine Attorney General.

E.

“Covered Conduct” shall mean the Defendant’s Advertising, Marketing
and Labeling practices regarding the Covered Products through the
Effective Date of this Judgment,

F.

“Covered Product” or “Covered Products” shall mean (i) any yogurt,
including but not limited to Activia yogurt; (ii) any dairy drink; and (iii)
any food or drink not covered by the foregoing that contains a Probiotic,
including, but not limited to, DanActive,

G.

“Defendant” or “Dannon” shall refer to The Dannon Company, Inc., a
Delaware corporation with its principal place of business in White Plains,
NY. For purposes of this Consent Judgment only, the term includes its
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successors and assigns and their officers, and each of the above’s agents,
representatives, and employees.
H.

“Disease” shall refer to damage to an organ, part, structure, or system of
the body such that it does not function properly (e.g, cardiovascular
disease), or a state of health leading to such dysfunctioning (e.g,
hypertension); except that diseases resulting from essential nutrient
deficiencies (e.g., scurvy, pellagra) are not included in this definition.

I.

“Effective Date” shall refer to the date that this Judgment is signed and
fully executed by the parties and approved by the Court. However, the
Effective Date as it affects existing Labeling shall be one hundred twenty
(120) days after this Judgment is signed and fully executed by the parties
and approved by the Court. All Covered Product manufactured after the
one hundred twenty (120) days shall have the revised Labeling. However,
the Effective Date for existing print Advertisements and broadcast
Advertisements shall be 90 days after this Judgment is signed and fully
executed by the parties and approved by the Court.

J.

“Essentially Equivalent Product” means a product that contains the
identical ingredients, except for inactive ingredients (e.g., inactive binders,
flavors, preservatives, colors, fillers, excipients), in the same form and
dosage, and with the same route of administration (e.g., orally,
sublingually), as the Covered Product; provided that the Covered Product
may contain additional ingredients or other differences in formulation to
affect taste, texture, or nutritional value (so long as the other differences
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do not change the form of the Productor involve the ingredients from
which the functional benefit is derived), if reliable scientific evidence
generally accepted by experts in the field demonstrates that the amount of
additional ingredients, combination of additional ingredients, and any
other differences in formulation are unlikely to impede or inhibit the
effectiveness of the ingredients in the Essentially Equivalent Product.
K.

“Including” shall mean including, without limitation.

L.

“Label” shall mean a display of written, printed or graphic matter upon
the immediate container of any article, or on the outside container or
wrapper, if any, of the retail package of such article.

M.

“Labeling” shall mean all Labels and other written, printed, or graphic
matter upon any article or any of its containers or wrappers, or
accompanying such article.

N.

“Marketing” shall mean any act or process or technique of promoting,
offering, selling or distributing a product or service.

O.

fProbiotics” shall mean live microorganisms, which when administered
in adequate amounts, confer a health benefit on the host, excluding the
cultures Streptococcus thermophihis and Lactobacillus bulgaricus.

P.

“Settling States” shall mean and include; Alaska, Arizona, Arkansas,
Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois,
Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts,
Michigan, Missouri, Montana, Nebraska, Nevada, New Hampshire, New
Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Oregon,
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Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee,
Texas, Vermont, Washington, West Virginia and Wisconsin.
Q.

“State/’ “State of Maine,” or “Attorney General” refers to the Plaintiff
and shall mean the Office of the Maine Attorney General.

III.
3,1.

JURISDICTION

Jurisdiction of this Court over the subject matter and over the Defendant for the

purpose of entering into and enforcing this Judgment is admitted. Jurisdiction is retained by this
Court for the purpose of enabling the State to apply to this Court for such further Judgments and
directions as may be necessary or appropriate for the construction, modification or execution of
this Judgment, including the enforcement of compliance therewith and remedies, penalties and
sanctions for violation thereof. The Defendant agrees to pay all court costs and attorneys’ fees
associated with any successful petition to enforce any provision of this Judgment against the
Defendant.

IV.
4 .1

VENUE

Pursuant to 5 M.R.S. §209, venue as to all matters between the parties relating

hereto or arising out of this Judgment shall be in Kennebec County, Maine.

V.

DEFENDANT

5 .1

The Defendant warrants and represents that it is the proper party to this Judgment.

5.2

The Defendant represents and warrants that the execution and delivery of this

Judgment is its free and voluntary act, and that this Judgment is the result of good faith
negotiations.
5.3

The Defendant represents and warrants that signatories to this Judgment have
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authority to act for and bind the Defendant,
5,4

The Defendant acknowledges that it understands that the State and this Court

expressly rely upon all representations and warranties in this Judgment, The Defendant further
acknowledges and understands that if any Defendant makes any false or deceptive representation
or warranty, the State has the right to vacate or set aside this Judgment, inter alia, in whole or in
part, and to move that the Defendant making such falso, or deceptive representation(s) or
vvarranty(ies) be held in contempt and to seek sanctions and remedies under any other law,
regulation or rule, together with any and all such other sanctions, remedies or relief as may be
available to the State in law or equity, if the State so elects.
VI.
6.1

APPLICATION OF JUDGMENT

The Defendant agrees that the duties, responsibilities, burdens and obligations

undertaken in connection with this Judgment shall apply to The Dannon Company, Inc., its
successors and assigns, and their officers, and each of the above’s agents, representatives, and
employees.
VII.
7.1

PERMANENT INJUNCTION

All of the requirements o f this section, Part Vìi, are cumulative and any

representation that Defendant makes shall comply with each and every provision in this Part VII
Except as provided in paragraph 7,2, upon entry of this Judgment, the Defendant, directly or
through any corporation, partnership, subsidiary, division, trade name, or other device, is hereby
permanently enjoined and restrained pursuant to 5 M.R.S. §209 from:
A,

Making any express or implied representation in connection with the
Advertising, Marketing, or Labeling of a Covered Product, including
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through the use of a product name, endorsement, depiction, or illustration,
which in the context of the Labeling, Advertisement, or Marketing
material, directly states or implies that such Product may be used in the
diagnosis, cure, mitigation, treatment, or prevention of a Disease,
including but not limited to:
1,

Using:
a,

the term L. casei Defemis\

b,

the phrase, “strengthens your body's defenses;” or

c,

any depictions, characters or vignettes that imply active
germ fighting;

2.

Representing that any Covered Product can be used to treat,
mitigate, cure or prevent diarrhea; provided, however, a
structure/funotion claim that the Covered Product supports or
promotes relief from temporary or occasional diarrhea is not
prohibited, if the Defendant possesses and relies upon competent
and reliable scientific evidence that is sufficient in quality and
quantity based on standards generally accepted in the relevant
scientific fields when considered in light of the entire body of
relevant and reliable scientific evidence that substantiates that the
representation is true. For purposes of this Paragraph, competent
and reliable scientific evidence means tests, analyses, research, or
studies that have been conducted and evaluated in an objective
manner by qualified persons and are generally accepted in the
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profession to yield accurate and reliable results.
3.

Representing that any Covered Product can be used to treat,
mitigate, cure, or prevent constipation, including through the use of
depictions to symbolize relief from constipation; provided,
however a structure/function claim that the Covered Product
supports or promotes relief from temporary and occasional
constipation is not prohibited, if the Defendant possesses and relies
upon competent and reliable scientific evidence that is sufficient in
quality and quantity based on standards generally accepted in the
relevant scientific fields when considered in light of the entire
body of relevant and reliable scientific evidence that substantiates
that the representation is true. For purposes of this Paragraph,
competent and reliable scientific evidence means tests, analyses,
research, or studies that have been conducted and evaluated in an
objective manner by qualified persons and are generally accepted
in the profession to yield accurate and reliable results,

4.

Using the word ‘'immunity,” or the phrase, "Z. casei immunitas”,
provided however, that a structure/function claim can be made for
the word “immunity,” or the phrase “Z. casei Immunitas” in which
(a) the Defendant clearly and conspicuously modifies the word
“immunity,” or the phrase, “Z. casei Immunitas” with a statement
that the Covered Product merely helps to promote, support or
maintain the immune system of persons who consume a Covered
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Product and (b) the Defendant possesses and relies upon competent
and reliable scientific evidence that is sufficient in quality and
quantity based on standards generally accepted in the relevant
scientific fields, when considered in light of the entire body of
relevant and reliable scientific evidence, to substantiate that the
representation is true, For purposes of this paragraph, competent
and reliable scientific evidence means tests, analyses, research, or
studies that have been conducted and evaluated in an objective
manner by qualified persons and are generally accepted in the
profession to yield accurate and reliable results.
5.

Citing, summarizing, or linking to clinical studies or research in
the Labeling of a Covered Product if the citation, summary, or link
to the clinical studies or research, in the context of the Labeling as
a whole, implies that a Covered Product or an ingredient in a
Covered Product treats, mitigates, cures, or prevents a Disease,
e.g.i placement on the immediate product labeling or packaging,
inappropriate prominence, or lack o f relationship to the Covered
Product’s express claims.

6.

Depicting a cellular wall fortified with a Covered Product that
repels all, or nearly all, of the depictions of germs.

B.

Making any express or implied representation in connection with the
Advertising, Marketing, or Labeling of a Covered Product, including
through the use of a product name, endorsement, depiction, or illustration,
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that such Product reduces the likelihood of getting a cold or the flu, which
in the context of the Labeling, Advertisement, or Marketing material,
directly states or implies that any Covered Product can be used to treat,
mitigate, or prevent a cold or the flu,
C.

Making any express or implied representation in connection with the
Advertising, Marketing or Labeling of Activia yogurt, including through
the use of a product name, endorsement, depiction, or illustration, that
Activia yogurt relieves temporary irregularity or helps with slow intestinal
transit time, unless the representation is non-misleading, conveys that
eating three servings a day is required to obtain the benefit and, at the time
the claim is made, the Defendant possesses and relies upon competent and
reliable scientific evidence that substantiates that the representation is true.
Provided, however, that nothing in this Paragraph shall prohibit Defendant
from representing that such benefit can be achieved from eating less than
three servings a day if such claim is non-misleading and Defendant
possesses and relies upon competent and reliable scientific evidence that
substantiates that the representation is true.
For purposes of paragraph 7.1(C), competent and reliable scientific
evidence shall consist of at least two Adequate and Well-Controlled
Human Clinical Studies of Activia yogurt, or of an Essentially Equivalent
Product, conducted by different researchers, independently of each other,
that conform to acceptable designs and protocols and whose results, when
considered in light of the entire body of relevant and reliable scientific

evidence, are sufficient to substantiate that the representation is true.
Defendant shall have the burden of proving that a product satisfies the
definition of Essentially Equivalent Product.
D.

Making any express or implied representation in connection with the
Advertising, Marketing or Labeling of any Covered Product other than
Activia yogurt, including through the use of a product name, endorsement,
depiction, or illustration, that such Product relieves temporary irregularity
or helps with slow intestinal transit time, unless the representation is non
misleading and, at the time the claim is made, the Defendant possesses and
relies upon competent and reliable scientific evidence that substantiates
that the representation is true. For purposes of paragraph 7.1 (D),
competent and reliable scientific evidence shall consist of at least two
Adequate and Well-Controlled Human Clinical Studies of the Covered
• Product, or of an Essentially Equivalent Product, conducted by different
researchers, independently of each other, that conform to acceptable
designs and protocols and whose results, when considered in light of the
entire body of relevant and reliable scientific evidence, are sufficient to
substantiate that the representation is true. Defendant shall have the
burden of proving that a product satisfies the definition of Essentially
Equivalent Product.

E.

Making any express or implied representation in connection with the
Advertising, Marketing or Labeling of a Covered Product, including
through the use of a product name, endorsement, depiction or illustration,
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about the health benefits, performance, efficacy or safety of a Covered
Product, unless the representation is non-misleading, and, at the time the
■ claim is made, the Defendant possesses and relies upon competent and
reliable scientific evidence that is sufficient in quality and quantity based
on standards generally accepted in the relevant scientific fields when
considered in light of the entire body of relevant and reliable scientific
evidence to substantiate that the representation is true,
For the purposes of paragraph 7.1(E), competent and reliable scientific
evidence means tests, analyses, research, or studies that have been
conducted and evaluated in an objective manner by qualified persons and
are generally accepted in the profession to yield accurate and reliable
results.
F.

Making, in connection with the Advertising, Marketing, or Labeling of a
Covered Product, any express or implied representation about the
existence, contents, methodology, statistical analyses, study scope,
validity, results, conclusions, or interpretations of any test, study, or
research that is false, misleading or deceptive, or that is misleading or
deceptive when considered together with other representations or
depictions.

G.

Using, in connection with the Labeling of a Covered Product, the term
Bifidus Regularis™, or any other fanciful term that expressly or impliedly
represents that a Covered Product helps regulate the digestive system
unless the Defendant clearly and conspicuously identifies the true
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scientific name of the bacteria, including its genus, species and strain.
H.

Using, in connection with the Labeling of a Covered Product, the term L.
casei Immunitas™, or any other fanciful term that expressly or impliedly
represents that a Covered Product supports, promotes, or maintains the
functioning of the immune system unless the Defendant clearly and
conspicuously identifies the true scientific name of the bacteria, including
its genus, species and strain.,

7.2

Additional Terms Governing Injunctive Relief
A.

Notwithstanding any of the foregoing provisions, Defendant, directly or
through any corporation, partnership, subsidiary, division, trade name, or
other device, is hereby permanently enjoined and restrained from making
any express or implied statement(s) in connection with the Advertising,
Marketing or Labeling of any Covered Product that is false, misleading, or
deceptive, or that is misleading or deceptive when considered together
with other representations or depictions; and from omitting any material
information such that an express or implied statement made by the
Defendant, directly or through any corporation, partnership, subsidiary,
division, trade name, or other device, is misleading or deceptive.

B.

Nothing in this Judgment shall prohibit Defendant, directly or through any
corporation, partnership, subsidiary, division, trade name, or other device,
from making any lawful, non-misleading, and non-deceptive
representation for any Covered Product that is: (i) specifically permitted in
Labeling for such Product by regulations promulgated by the Food and
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Drug Administration pursuant to the Nutrition Labeling and Education Act
of 1990; (ii) lawful for the Covered Product under the Federal Food Drug
and Cosmetic Act; (iii) lawful for the Covered Product under any final
regulation promulgated by the Food and Drug Administration; (iv) lawful
for the Covered Product under any new drug application applicable to
such Product approved by the Food and Drug Administration; (v) part of
the lawful marketing for the Covered Product of a homeopathic drug; (vi)
part of the lawful marketing for the Covered Product of a Medical Food
under the Orphan Drug Amendments of 1998; or (vii) lawful for the
Covered Product under a FDA monograph of an over-the-counter drug.
The failure of the FDA, FTC, or other law enforcement agency to take an
enforcement action, or the mere presence of a representation, statement, or
claim in the marketplace does not mean a representation, statement, or
claim is lawful.
VIII. COMPLIANCE
8.1

Pursuant to 5 M.R.S. §209, the Defendant shall, in connection with the

Advertising, promotion, offering for sale, or distribution in or from Maine of any Covered
Product;
A.

Take reasonable steps sufficient to monitor and ensure that the Defendant
complies with this Judgment. In conducting periodic monitoring of
compliance, the Defendant shall document and retain sufficient evidence
to detail and substantiate its monitoring efforts and produce such
documentation as may be requested by the State within thirty (30) days of
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such a request.
B.

Conduct periodic reasonable monitoring of representations made by the
Defendant concerning any Covered Product when the relevant actors are
engaged in sales or other customer service functions, including
representations made orally or through electronic communications. For a
period of five (5) years from the date of entry of this Judgment, in
conducting periodic monitoring of the representations made by the
Defendant concerning any Covered Product, the Defendant shall
document and retain sufficient evidence to detail and substantiate its
monitoring efforts and produce such documentation to the State within
thirty (30) days of such a request.

C.

Conduct periodic reasonable monitoring of representations made about
any Covered Product on all Internet websites operated or maintained by
the Defendant or anyone doing so on their behalf. For a period of five (5)
years from the date of entry o f this Judgment, in conducting periodic
monitoring of representations made about any Covered Product on
Internet websites operated or maintained by the Defendant or anyone
doing so on its behalf, the Defendant shall document and retain sufficient
evidence to detail and substantiate their monitoring efforts and produce
such documentation and records as may be requested by the State within
thirty (30) days of such a request.

D.

Take appropriate disciplinary action against any employee or agent who
knew or should have known that he or she had engaged in any conduct
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prohibited by this Judgment, up to and including termination of any such
employment or agency relationship, within a reasonable period of time not
to exceed thirty (30) days after the Defendant knows or should have
known that such person is, or has been, engaging in such conduct.
E.

Within sixty (60) days after entry of this Judgment, send an exact copy of
this Judgment to each of the Defendant’s directors, officers, and any
employee, agent, or third party who creates, reviews, or edits the
Defendant’s Advertising, Marketing or Labeling of Covered Products. The
Defendant shall document and retain sufficient evidence to confirm
distribution as required by this paragraph and shall produce such
documentation to the State within thirty (30) days of such a request.

F.

Within 60 days of entry of this Judgment, institute a reasonable program
of surveillance that is adequate to reveal whether the Defendant is
disseminating in or from Maine any Advertising, Marketing or Labeling
material that contains any representation that violates the provisions of this
Judgment. For a period of five (5) years from the date of entry of this
Judgment, the Defendant shall document and retain sufficient evidence to
detail and substantiate its program of surveillance and shall produce such
documentation to the State within thirty (30) days of such a request.

G.

Promptly, and in a reasonable manner, investigate any information the
Defendant receives that any retailer or other third party in Maine is using
or disseminating any Advertisements or Marketing material, or making
any oral statements, that violate the provisions of this Judgment, and send
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Exhibit A to any retailer or other third party whose Advertisements or
Marketing materials of a Covered Product may violate the terms of this
Judgment if made by the Defendant. For a period o f five (5) years from
the date of entry o f this Judgment, the Defendant shall document and
retain sufficient evidence to detail and substantiate their investigation
efforts and shall produce such documentation to the State within thirty
(30) days o f such a request.

IX.
9.1

PAYMENT TO THE STATES

No later than thirty (30) days after the Effective Date o f this Judgment, Dannon

shall pay a total amount of $21 million to the Office of the Attorney General of Temiessee
through electronic funds transfer. The Tennessee Attorney General shall divide and distribute
these funds to each Signatory Attorney General o f the Multistate Working Group5in an amount
to be designated by, and in the sole discretion of, the Multistate Executive Committee.

Said

payment shall be used by the States as and for attorneys’ fees and other costs o f investigation and
litigation, or to be placed in, or applied to, the consumer protection enforcement fund, including
future consumer protection enforcement, consumer education, litigation or local consumer aid
fund or revolving fund, used to defray the costs o f the inquiry leading hereto, or for other uses
permitted by state law including contributions to nutrition and nutrition education programs, at
the sole discretion of each Signatory Attorney General.

1The Working Group consists o f Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida,
Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan,
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio,
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Tennessee, Vermont,
Washington, West Virginia and Wisconsin.

1 The Executive Committee consists of Arizona, Florida, Kentucky, North Carolina, Ohio, Oregon, Texas,
Tennessee, and Wisconsin.
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X.
10.1

GENERAL PROVISIONS

The acceptance of this Judgment by the State shall not be deemed approval by the

State of any of the Defendant’s advertising or business practices. Further, neither the Defendant
nor anyone acting on its behalf shall state or imply, or cause to be stated or implied, that the State
or any other governmental unit of the State has approved, sanctioned or authorized any practice,
act, advertisement or conduct of the Defendant.
10.2

This Judgment may only be enforced by the State, the Defendant, and this Court.

10.3

The titles and headers to each section of this Judgment are for convenience

purposes only and are not intended by the parties to lend meaning to the actual provisions of the
Judgment.
10.4

Nothing in this Judgment shall limit the State’s right to obtain information,

documents or testimony from the Defendant pursuant to any state or federal law, regulation or.
rule.
10.5

Nothing in this Judgment shall be construed to limit the authority of the Attorney

General to protect the interests of the State or consumers. Except as provided in Section XII of
this Judgment, this Judgment shall not bar the State, or any other governmental entity from
enforcing laws, regulations or rules against the Defendant.
10.6

It is the intent of the Parties that this Judgment not be admissible in other actions

or binding on the Defendant in any respect other than in connection with the enforcement of this
Judgment.
10.7

No waiver, modification, or amendment of the terms of this Judgment shall be

valid or binding unless made in writing, signed by the party to be charged, approved by this
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Court and then only to the extent specifically set forth in such written waiver, modification or
amendment.
10.8

Any failure by any party to this Judgment to insist upon the strict performance by

any other party of any of the provisions of this Judgment shall not be deemed a waiver of any of
the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance of any and all of the provisions of this
Judgment and the imposition of any applicable penalties, including but not limited to contempt,
civil penalties as set forth in 5 M.R.S. §209 and/or the payment of attorneys fees to the State and
other applicable state law.
10.9

If any clause, provision or section of this Judgment shall, for any reason, be held

illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall not affect
any other clause, provision or section of this Judgment and this Judgment shall be construed and
enforced as if such illegal, invalid or unenforceable clause, section or other provision had not
been contained herein.
10.10 Time shall be of the essence with respect to each provision of this Judgment that
requires action to be taken by the Defendant within a stated time period or upon a specified date.
10.11 Nothing in this Judgment shall be construed to waive any claims of.Sovereign
Immunity the State may have in any action or proceeding.
10.12 This Judgment sets forth the entire agreement between the parties, and there are
no representations, agreements, arrangements, or understanding, oral or written, between the
parties relating to the subject matter of this Judgment which are not fully expressed hereto or
attached hereto.
10.13 The Defendant will not participate, directly or indirectly, in any activity or form a
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separate entity or corporation for the purpose of engaging in acts or practices in whole or in part
in the State which are prohibited in this Judgment or for any other purpose which would
otherwise circumvent any part of this Judgment or the spirit or purposes of this Judgment.
10A 4 The Defendant has provided the State with certain documents, advertisements,
and contracts. The Defendant acknowledges and agrees that providing these documents to the
State(s) in no way constitutes the State’s pre-approval, review for compliance with state or
federal law, or with this Judgment, or a release of any issues relating to such documents.
10.15 The Defendant further agrees to execute and deliver all authorizations, documents
and instruments which are necessary to carry out the terms and conditions of this Judgment.
10.16 This document may be executed in any number of counterparts and by different
signatories on separate counterparts, each of which shall constitute an original counterpart hereof
and all o f which together shall constitute one and the same document. One or more counterparts
of this Judgment may be delivered by facsimile or electronic transmission with the intent that it
or they shall constitute an original counterpart thereof.
XI.
11.1

COMPLIANCE WITH ALL LAWS

Nothing in this Judgment shall be construed as relieving the Defendant of the

obligation to comply with all state and federal laws, regulations or rules, nor shall any of the
provisions of this Judgment be deemed to be permission to engage in any acts or practices
prohibited by such law, regulation, or rule.
11.2

Nothing in this Judgment shall require the Defendant to: (A) take an action that is

otherwise prohibited by the Constitution, laws or rules or regulations made there under, of the
United States or Maine; or (B) fail to take an action which is so required.
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XII.
12.1

RELEASE

Nothing in this Judgment shall impair or limit the private right of action that any

consumer, person, or entity may have against the Defendant.
12.2

By execution of this Judgment and following a full and complete payment to the

States, the State of Maine releases and forever discharges to the fullest extent of the law, the
Defendant, as defined above, from the following: all civil claims, causes of action, damages,
restitution, fines, costs, and penalties that the Maine Attorney General could have asserted
against the Defendant under the Maine Unfair Trade Practices Act, 5 M.R.S. §207 et.seq.
resulting from the Covered Conduct up to and including the Effective Date that is the subject of
this Judgment.
12.3

Notwithstanding any term of this Judgment, any and all of the following forms of

liability are specifically reserved and excluded from the Release in Section 12.2 as to any entity
or person, including the Defendant:
A.

Any criminal liability that any person or entity, including the Defendant,
has or may have to the State of Maine.

B.

Any civil or administrative liability that any person or entity, including the
Defendant, has or may have to the State of Maine under any statute,
regulation or rule not expressly covered by the release in Section 12.2
above, including but not limited to, any and all of the following claims:

C.

(i)

State or federal antitrust violations; or

(ii)

State or federal tax claims.

Any liability under the State of Maine’s above-cited consumer protection
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laws that any person and/or entity, including the Defendant has or may
have to individual consumers, persons, or entities.
XIII. DISPUTES REGARDING COMPLIANCE
13.1

For the purposes of resolving disputes with respect to compliance with this

Judgment, should the Attorney General have a reasonable basis to believe that the Defendant has
engaged in a practice that violates a provision of this Judgment subsequent to the Effective Date
of this Judgment, then the Attorney General shall notify the Defendant in writing of the specific
objection, identify with particularity the provisions of this Judgment that the practice appears to
violate, and give the Defendant thirty (30) calendar days to respond to the notification; provided,
however, that the Attorney General may take any action where the Attorney General concludes
that, because of the specific practice, a threat to the health or safety of the public requires
immediate action.
13.2

Upon receipt of written notice and within the thirty (30) calendar-day period, the

Defendant shall provide a good faith written response to the Attorney General's objection. The
response shall include an affidavit containing either:
A.

A statement explaining why the Defendant believes it is in compliance
with the Judgment; or

B.

A detailed explanation of how the alleged vioiation(s) occurred; and
i.

A statement that the alleged violation has been remedied and how
it has been remedied; or

ii.

A statement that the alleged violation cannot be reasonably
remedied within thirty (30) calendar days from receipt of the
notice, but (1) the Defendant has begun to take corrective action to
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remedy the violation; (2) the Defendant is pursuing such corrective
action with reasonable and due diligence; and (3) the Defendant
has provided the Attorney General with a detailed and reasonable
time table for remedying the alleged violation.
13.3

Nothing herein shall prevent the Attorney General from agreeing in writing to

provide the Defendant with additional time beyond the thirty (30) calendar-day period to respond
to the notice.
13.4

Nothing herein shall be construed to exonerate any failure to comply with any

provision of this Judgment after the date of entry or to compromise the authority of the Attorney
General to initiate a proceeding for failure to comply. Further, nothing in this section shall be
construed to limit the authority of the Attorney General to protect the interests of the State.
13.5

The Attorney Genera! represents that he or she will seek enforcement of the

provisions of this Judgment with due regard for fairness and, in so doing, shall take into account
efforts that the Defendant has taken to remedy any claimed violation of this Judgment.
13.6

Upon giving the Defendant thirty (30) calendar days to respond to the notification

described in Paragraph 13.1 above, the Attorney General shall be permitted to request and the
Defendant shall produce relevant, non-privileged, non-work-product records and documents in
the possession, custody or control of the Defendant that relate to its compliance with each
provision of this Judgment as to which legally sufficient cause has been shown.
XIV. NOTIFICATION TO STATE
14.1

For five (5) years following execution o f this Judgment, the Defendant shall

notify the State, in writing at least thirty (30) calendar days prior to the effective date of any
proposed changes in its corporate structure, such as dissolution, assignment, or sale resulting in
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the emergence of a successor corporation or firm, the creation or dissolution of subsidiaries, or
any other changes in the Defendant’s status that may impact in any way compliance with
obligations arising out of this Judgment.
] 4.2

Any notices required to be sent to the State or the Defendant by this Judgment

shall be sent by United States mail, certified mail return receipt requested or other nationally
recognized courier service that provides for tracking services and identification of the person
signing for the document. The documents shall be sent to the following addresses:

For the State Attorney General:
Consumer Division
Office of the Attorney General
U6 State House Station
Augusta, ME 04333-0006
For the Defendant:
Sarah Reznek
Bingham McCutchen LLP
2020K Street, NW
Washington, DC 20006-1806

XV.
15.1

PAYMENT OF COURT COSTS

All court costs associated with this action and any other incidental costs or

expenses incurred in this action thereby shall be borne by the Defendant. No costs shall be taxed
to the State. Further, no discretionary costs shall be taxed to the State.
XVI.
16.1

PENALTY FOR FAILURE TO COMPLY

Any failure by the Defendant to comply with or any violation by the Defendant of

the terms of this Consent Judgment shall be punishable in accordance with 5 M.R.S, §209 and
the State of Maine shall be free to pursue any and all remedies contained within 5 M.R.S. §209.
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IT IS SO ORDERED, ADJUDGED, AND DECREED.

JOINTLY APPROVED AND
SUBMITTED FOR ENTRY:

Respectfully submitted,
JANET T. MILLS
Attorney General

"nomas A, Harnett, AAG
Civil Rights Education and Enforcement
Maine Bar No.: 6808

Office of the Attorney General
Six State House Station
Augusta, Maine 04333
(207) 626-8897
Attorneys for State of Maine
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FOR THE DANNON COMPANY, INC.

Bingham McCutchen LLP
2020 K Street, N.W.
Washington, D.C. 20006
Tel: (202) 373-6218
Fax: (202) 373-6491
Email: nicholas.gess@bingham.com
ME Bar No. 002504
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T H E HANNON COM PANY, INC.
100 Hillside Avenue
White Plains, NY 10603
Phone: 914-872-8400
Fax: 914-872-1554

By:
Kenneth Stride
Title: Vice President and Secretary
Date: December 9, 2010

Bingham McCutchen LLP
National Counsel for T H E B A N N 0N COMPANY, INC.

Washington, DC 20006-1806
Phone: 202-373-6171
Fax:202-373-6001
Date:

A/73586972.t
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EXHIBIT A
GOVERNMENT-ORDERED DISCLOSURE
[on Dannon Company, Inc., letterhead]
[Insert Date]
[Addressee]
Dear Dannon Company, Inc., Distributor, Reseller, or Retailer:
The Dannon Company, Inc., (Dannon) recently reached a settlement with the
Attorneys General of thirty-eight states and the State of Hawaii, Office of Consumer Protection
(State AGs) resolving an investigation into what the State AGs believed to be unsubstantiated
and/or deceptive and unlawful claims concerning Dannon’s Activia and DanActive products.
Although we dispute the views of the State AGs and deny any wrongdoing, we have agreed to
resolve the State AGs’ investigation.
Dannon will work with you to ensure the advertisements that you distribute are in
compliance with the Settlement Agreement. To comply with the Settlement Agreement reached
with the State AGs, Dannon offers its assistance in ensuring that the advertising or promotional
materials that you disseminate regarding Activia and DanActive products will be in compliance
with the terms of the Settlement Agreement, including claims identified in the Consent
Judgment. Such claims about Activia and DanActive products may only be made if they are
true, adequately substantiated and otherwise permitted by law as stated in the Settlement
Agreement.
A copy of the settlement with the State AGs is attached. If you have any
questions, please call [insert name and telephone numbers of the responsible Dannon Company,
Inc. Attorney or Officer].
Sincerely,
The Dannon Company, Inc.
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